Our data suggest that DR6 contributes to the malignant progression of CRC by activating AKT/NF-κB pathway, indicating its clinical potential as a prognostic marker and therapeutic target for CRC. This evidence concerns the gene TNFRSF21 and colorectal carcinoma.